6533b7d0fe1ef96bd125b7a9

RESEARCH PRODUCT

Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review

Domenico Di RaimondoSalvatore Santo SignorelliMarco MangiaficoIngrid PlataniaSalvatore D. TomaselloAgostino GaudioGiuliana Barcellona

subject

Malemedicine.medical_specialtyaspirinHealth Toxicology and Mutagenesisdipyridamolelcsh:MedicineStroke.Review030204 cardiovascular system & hematology03 medical and health sciencesTherapeutic approach0302 clinical medicinePharmacotherapyDouble-Blind MethodpreventionSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineStrokeAgedclopidogrelAspirinPreventive strategybusiness.industrylcsh:RPublic Health Environmental and Occupational HealthMiddle AgedClopidogrelmedicine.diseasestrokecombined drug therapyClinical trialDiabetes Mellitus Type 2Ischemic Attack TransientStroke preventionDrug Therapy CombinationFemalebusinesscilostazolPlatelet Aggregation Inhibitors030217 neurology & neurosurgerymedicine.drug

description

Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the review were organized to show both benefits or consequences from antiplatelet pharmacotherapy. Conclusively, this review provides a potential synopsis on the most appropriate therapeutic approach for stroke prevention in clinical practice.

https://doi.org/10.3390/ijerph17165840